Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study

Karoline Krause(Humboldt-Universität zu Berlin), Marcus Maurer(Humboldt-Universität zu Berlin), Jörg Fischer(Universitätsklinikum Tübingen), Martin Metz(Humboldt-Universität zu Berlin), Karsten Weller(Humboldt-Universität zu Berlin), Martin K. Church(Southampton General Hospital), Athanasios Tsianakas(University Hospital Münster), Nicola Wagner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Journal of Allergy and Clinical Immunology
September 19, 2016
10.1016/j.jaci.2016.07.041
Cited by 104

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
|New England Journal of Medicine|2013|1.1k
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|429